Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
26.94
+1.14 (4.42%)
At close: Jul 10, 2025, 4:00 PM
25.60
-1.34 (-4.97%)
After-hours: Jul 10, 2025, 4:00 PM EDT
Palvella Therapeutics Employees
Palvella Therapeutics had 14 employees as of December 31, 2024.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,634,929
Market Cap
297.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
PVLA News
- 10 days ago - Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes - GlobeNewsWire
- 17 days ago - Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% - GlobeNewsWire
- 22 days ago - Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - GlobeNewsWire
- 4 weeks ago - Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - GlobeNewsWire
- 6 weeks ago - Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer - GlobeNewsWire
- 2 months ago - Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 - GlobeNewsWire
- 2 months ago - Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 - GlobeNewsWire